AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 101 filers reported holding AVADEL PHARMACEUTICALS PLC in Q2 2023. The put-call ratio across all filers is 0.87 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $24,084,510 | -45.1% | 2,338,302 | -12.2% | 1.68% | -53.7% |
Q2 2023 | $43,903,972 | +28.4% | 2,664,076 | -28.6% | 3.64% | -9.4% |
Q1 2023 | $34,192,246 | +27.9% | 3,732,778 | 0.0% | 4.02% | +43.7% |
Q4 2022 | $26,726,690 | +42.9% | 3,732,778 | 0.0% | 2.79% | +56.2% |
Q3 2022 | $18,701,000 | +105.3% | 3,732,778 | 0.0% | 1.79% | +103.3% |
Q2 2022 | $9,108,000 | -64.3% | 3,732,778 | 0.0% | 0.88% | -64.1% |
Q1 2022 | $25,495,000 | -15.5% | 3,732,778 | 0.0% | 2.45% | -10.3% |
Q4 2021 | $30,161,000 | +21.9% | 3,732,778 | +47.8% | 2.74% | +133.2% |
Q3 2021 | $24,749,000 | +47.4% | 2,525,452 | +1.2% | 1.17% | +33.8% |
Q2 2021 | $16,795,000 | -25.6% | 2,495,573 | 0.0% | 0.88% | -43.5% |
Q1 2021 | $22,560,000 | +78.5% | 2,495,573 | +31.9% | 1.55% | +37.4% |
Q4 2020 | $12,639,000 | +31.6% | 1,892,043 | -0.7% | 1.13% | -28.0% |
Q3 2020 | $9,606,000 | -37.7% | 1,905,990 | -0.1% | 1.57% | -38.8% |
Q2 2020 | $15,413,000 | +43.2% | 1,907,504 | +25.7% | 2.56% | +3.6% |
Q1 2020 | $10,767,000 | – | 1,517,296 | – | 2.47% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |